Intact IGFBP-3 ELISA

IGFBP-3 exhibits intrinsic growth-regulating effects that are not yet fully understood, but have evoked interest with regards to a possible role of IGFBP-3 as a prognostic tumor marker. Low IGFBP-3 and IGF-I levels are observed in GH deficiency or GH resistance, also epidemiologic studies suggest that low IGFBP-3 is associated with greater risk of aggressive, metastatic prostate cancers. The elevated serum IGFBP-3 and IGF-I levels indicate a sustained overproduction of GH, or excessive rhGH therapy. Both conditions are associated with generalized organomegaly, hypertension, diabetes, cardiomyopathy, osteoarthritis, and diminished longevity.

The Ansh Labs’ Intact IGFBP-3 ELISA is a quantitative two-step sandwich type immunoassay. The immunoassay methods designed for the measurement of bioactive IGF-I, total and Intact IGFBP-3 in patient samples could be of practical value for the diagnosis or prediction of various pathologies including growth abnormalities and cancer. The Intact IGFBP-3 Assay uses an acidification and neutralization method to dissociate Intact IGFBP-3 from all the binding subunits. Intact IGFBP-3 levels are quantified in the extracted samples using a highly sensitive and specific Intact IGFBP-3 ELISA. Total IGFBP-3 levels can be measured using Total IGFBP-3 ELISA (AL-120).

• Wide dynamic range of 3.5-117 ng/mL
• Sensitive to 1.37 ng/mL
• Total 1.5 hr incubation at RT
• Long shelf life of 24 months

Research Use Only within the United States. Ansh Labs is an FDA registered manufacturer of diagnostic test kits, antibodies, antigens, and proteins.